Stem Cell Therapy and Congenital Heart Disease

Area of Science:

• Regenerative Medicine
• Pediatric Cardiology
• Biotechnology

Background:

• Stem cell therapy has been extensively studied for adult heart disease for over a decade.
• Encouraging results in adults suggest potential applications for pediatric populations, particularly for congenital heart disease (CHD).
• Current evidence for stem cell efficacy in pediatric cardiac repair is mainly from case reports and limited pre-clinical models.

Purpose of the Study:

• To review the current knowledge on stem cell therapy and tissue engineering for children with CHD.
• To discuss the gaps in current research and future perspectives for cell-based strategies in treating pediatric CHD.
• To explore the potential of preemptive cardiac regeneration in the pediatric setting.

Main Methods:

• Review of existing literature on stem cell therapy and tissue engineering in pediatric CHD.
• Analysis of findings from clinical case reports and pre-clinical models.
• Examination of results from recent trials, such as the TICAP trial, investigating intracoronary infusion of cardiosphere-derived cells.

Main Results:

• Stem cell therapy is emerging as a new paradigm for treating pediatric congenital heart disease.
• The TICAP trial demonstrated the safety and feasibility of intracoronary infusion of autologous cardiosphere-derived cells in children with hypoplastic left heart syndrome.
• Early data suggests potential for stem cell products to promote cardiac repair and recovery in infants with dilated cardiomyopathy and structural heart disease.

Conclusions:

• Stem cell therapy holds significant promise for treating pediatric heart conditions, including CHD.
• Further research is needed to address gaps in knowledge regarding optimal cell types, delivery methods, and timing for pediatric cardiac regeneration.
• Future cell-based strategies could offer new therapeutic avenues for acquired cardiac diseases as well.